This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading, AI training
Expertise
Specializes in:
Medical: Pharmaceuticals
Medical: Health Care
Medical (general)
Volunteer / Pro-bono work
Open to considering volunteer work for registered non-profit organizations
Rates
General rate: 1 CNY per word / 250 CNY per hour
Portfolio
Sample translations submitted: 1
Chinese: Clinical Pharmacology General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - Chinese The phase 3 trial (CRPC2) was a randomized, placebo-controlled, double blind trial in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy. Patients were randomized 2:1 to receive either enzalutamide (160 mg daily) (N=800) or placebo (N=399). The primary endpoint was overall survival (OS), and the final analysis showed that OS was statistically significantly prolonged on the enzalutamide arm compared to the placebo arm. Based on the results of Phase 3 trial, no exposure-response relationship for the efficacy endpoint of overall survival (OS) could be identified for enzalutamide within a single fixed dose of 160 mg/day. There were no clinically meaningful exposure-response relationships for fatigue, flushing, headache, or hypertension within the limited exposure range for 160 mg/day. The effect of enzalutamide 160 mg/day at steady state on the QTc interval was evaluated in 796 patients with castration-resistant prostate cancer. No large difference (i.e., greater than 20 ms) was observed between the mean QT interval change from baseline in patients treated with XTANDI and that in patients treated with placebo, based on the Fridericia correction method.
Following oral administration of enzalutamide at 160 mg in patients with metastatic CRPC, the median time to reach maximum plasma enzalutamide concentrations is 1 hour (range 0.5 to 3 hours). The enzalutamide mean terminal elimination half-fife (T1/2), in patients with metastatic CRPC, following a single oral dose is 5.8 days (range 2.8 to 10.2 days). With daily dosing regimen, enzalutamide steady state is achieved by Day 28, and enzalutamide accumulates approximately 8.3-fold relative to a single dose. Daily fluctuations in enzalutamide plasma concentrations are low (mean peak-to trough ratio of 1.25). At steady state, enzalutamide shows approximately dose proportional pharmacokinetics over the daily dose range of 30 to 360 mg. In patients with MCRP cancer, the mean (%CV) predose Cmin values for enzalutamide and M2 were 11.4 (25.9%) µg/mL and 13.0 (29.9%) µg/mL, respectively.
I am a medical translator and editor working between English and Chinese, with a clinical medicine background and hands-on experience in medical writing, terminology review, and bilingual content alignment.
My work focuses on medical and healthcare content, including clinical research materials, medical reports, patient records, scientific literature, pharmaceutical texts, and medical MTPE. With training in translation and practical clinical experience, I am able to understand medical concepts accurately and render them into clear, natural, and professional target-language text.
I am familiar with CAT tools such as Trados and MemoQ, and I pay close attention to terminology consistency, logical accuracy, and style adaptation. I am particularly interested in medical translation, editing, MTPE, and content review projects that require both language precision and subject-matter understanding.
Portfolio